Cetuximab and chemotherapy in the treatment of patients with initially “nonresectable” colorectal (CRC) liver metastases: Long-term follow-up of the CELIM trial.
Gunnar Folprecht
Consultant or Advisory Role - Merck KGaA; Roche/Genentech
Thomas Gruenberger
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono
Research Funding - Merck Serono
Wolf Bechstein
Honoraria - Merck KGaA
Hans-Rudolf Raab
No relevant relationships to disclose
Juergen Weitz
No relevant relationships to disclose
Florian Lordick
Consultant or Advisory Role - Amgen; Fresenius ; GANYMED Pharmaceuticals; Roche
Honoraria - Amgen; Fresenius ; Roche
Research Funding - GlaxoSmithKline; Merck KGaA; Sanofi
Joerg Thomas Hartmann
Honoraria - Merck KGaA; Sanofi
Research Funding - Merck KGaA
Expert Testimony - Merck KGaA
Hauke Lang
No relevant relationships to disclose
Tanja Trarbach
Consultant or Advisory Role - Amgen; GANYMED Pharmaceuticals; iOMEDICO; Merck KGaA; Roche; Sanofi
Honoraria - Amgen; GANYMED Pharmaceuticals; iOMEDICO; Merck KGaA; Roche; Sanofi
Jan Stoehlmacher-Williams
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono
Torsten Liersch
No relevant relationships to disclose
Detlev Ockert
No relevant relationships to disclose
Dirk Jaeger
No relevant relationships to disclose
Ulrich Steger
No relevant relationships to disclose
Thomas Suedhoff
No relevant relationships to disclose
Claus-Henning Kohne
Honoraria - Merck KGaA; Pfizer